Cogent Biosciences Secures $866M Cash Runway into 2028, Eyes Dual Bezuclastinib Launches
Cogent closed Q1 2026 with $866.4 million in cash—bolstered by $45.7 million ATM proceeds and $18.0 million non-recurring payments—extending runway into 2028. The company has two bezuclastinib NDAs under FDA review, plans a third H1 2026 filing, and targets dual SM and GIST launches after pivotal Phase 3 PEAK data presentation.
1. First Quarter Financial Results
Cogent ended Q1 2026 with $866.4 million in cash, including $45.7 million from ATM proceeds and $18.0 million in non-recurring payments, providing funding into 2028. R&D spending rose to $75.4 million on expanded preclinical programs and one-time FGFR wind-down costs, while G&A increased to $28.2 million, driving a net loss of $97.4 million.
2. Bezuclastinib Regulatory and Trial Updates
Two NDAs for bezuclastinib are under FDA review—one for GIST and one for Non-Advanced Systemic Mastocytosis with a PDUFA date of December 30, 2026—and a third NDA for Advanced Systemic Mastocytosis is planned for H1 2026. Pivotal Phase 3 PEAK data in GIST will be presented at the May 2026 ASCO meeting, and Breakthrough Therapy designation plus RTOR submission aim to accelerate approval.
3. Pipeline Advancements and Upcoming Milestones
Cogent initiated Phase 1 studies for CGT4255 (ErbB2 inhibitor) and CGT6297 (PI3Kα inhibitor) and plans IND submissions for pan-KRAS and JAK2 V617F inhibitors in H1 2026. The company is preparing Phase 2 trials combining bezuclastinib with sunitinib in first-line GIST and building commercial infrastructure ahead of potential H2 2026 launches.